Formulation and Characterization of Drug Loaded Aquasomes for Effective Treatment of Type 2 Diabetes

Glibenclamide (Glyburide) is a powerful oral antidiabetic agent and orally active second-generation sulphonyl urea drug used in the reduction of blood sugar of patients with type of diabetes mellitus (NIDDM). Glibenclamide is short half-life of 4-6 hours. Development and evaluation of aquasomes of Glibenclamide for controlled/sustained drug release is the objective of this study. The aquasomes were prepared using calcium phosphate co ceramic with polyhydroxy oligomers sucrose/trehalose/lactose/cellobiose with 1:1 ,1:1.5 or 1:2 ratios. The prepared aquasomes were analysed for particle size, shape and FTIR study, % drug entrapment efficiency, zeta potential, in - vitro drug release studies. The percentages of drug entrapment efficiency and drug loading for the various aquasome formulations (F-1 to F-12) and they were found to be 79.8+-0.03, to 93.0+-0.05% and 7.1+-0.03% to 7.8+-0.03. It was found that the entrapment efficiency and drug loading was high for the lactose-coated Glibenclamide aquasomes of 1:2 core-to-core ratio formulation (F-12). By performing in vitro drug release study it was observed that the drug release of Glibenclamide from all the formulations was zero order kinetics. Stability studies for one month revealed that the formulations were stable till 400C at relative humidity of 75%. This outcome from release profiling strongly recommends that developed Glibenclamide loaded aquasomes can be useful delivery carrier to deliver drug in controlled release manner which is a prime requirement for the treatment of type II Diabetes mellitus (NIDDM).